Lipid exchange of apolipoprotein A-I amyloidogenic variants in reconstituted high-density lipoprotein with artificial

Yubexi Correa1, Mathilde Ravel1, Marie Imbert1

  • 1Biofilm - Research Center for Biointerfaces and Department of Biomedical Science, Faculty of Health and Society, Malmö University, Malmö, Sweden.

Insights

Reconstituted HDL (rHDL) with amyloidogenic apolipoprotein A-I (ApoA-I) variants showed reduced lipid removal from membranes. This suggests protein structure, not just lipid content, is key for HDL function in reverse cholesterol transport.

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Biophysics

Background:

  • High-density lipoproteins (HDLs) facilitate reverse cholesterol transport, crucial for preventing cardiovascular disease.
  • Apolipoprotein A-I (ApoA-I) is the primary protein in HDL, essential for its structure and function.
  • Amyloidogenic ApoA-I variants, despite their association with disease, exhibit enhanced cholesterol removal capabilities.

Purpose of the Study:

  • To investigate the impact of protein cargo and lipid composition on reconstituted HDL (rHDL) function.
  • To explore the structural and functional characteristics of rHDL containing ApoA-I amyloidogenic variants (G26R or L174S).
  • To understand how ApoA-I variants influence lipid-protein interactions and cholesterol efflux.

Main Methods:

  • Fourier transformed infrared spectroscopy and neutron reflectometry were used to analyze rHDL.
  • Small-angle X-ray scattering (SAXS) was employed to determine particle structure.
  • Lipid exchange capacities of rHDL particles with artificial membranes were assessed.

Main Results:

  • rHDL containing ApoA-I amyloidogenic variants demonstrated a significantly lower capacity for lipid removal compared to native ApoA-I rHDL.
  • The lipid removal efficiency was dependent on phospholipid unsaturation and rHDL ultrastructure.
  • Distinct structural and functional differences were observed between rHDL particles with native and variant ApoA-I.

Conclusions:

  • The protein cargo, specifically ApoA-I variants, plays a critical role in determining rHDL structure and function.
  • Amyloidogenic ApoA-I variants may not be ideal for therapeutic rHDL due to reduced lipid removal capacity.
  • Understanding lipid-protein interactions is vital for designing effective HDL-based therapies.